Resmed Inc is in the spotlight with various developments being reported. The company faces an ongoing investigation into potential
violations of securities laws, initiated by Levi & Korsinsky. Meanwhile, the company's CEO,
Michael Farrell, has reportedly sold $1.95m of its stocks. Occurring alongside are business advancements, including the acquisition of
VirtuOx and the launch of the
NightOwl Device for home sleep apnea testing in the US. It also reported
strong Q3 earnings with revenue surpassing estimates. This robust financial performance contributes to ResMed's reputation as a top growth stock. Despite a dip in the stock price post Q4 sales announcement, the company demonstrated its market strength with a 3.8% jump. Analysts have varied opinions about the stock's future, with some firms lowering price targets due to economic concerns, and others raising targets in response to positive outlooks.
Jim Cramer described RMD as a “remarkable Stock” commending its strong performance amidst wider market instability.
Resmed RMD News Analytics from Tue, 27 Aug 2024 07:00:00 GMT to Sat, 10 May 2025 02:56:34 GMT -
Rating 4
- Innovation 2
- Information 9
- Rumor -6
